drugset

drugset / Trial / NCT01632358

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

NCT01632358 ↗

Phase 1 Completed 279 enrolled Novartis Pharmaceuticals

CrossoverQuadruple-blindTreatment

Summary

The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.

Timeline

Start: 2012-06
Primary completion: 2012-12
Completion: 2012-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TAP311	Unknown	—	Oral

Indications